Rare Disease

Care4Rare is a nation-wide research program focusing on the improvement of both the diagnosis and treatment of rare diseases. Led out of the Children’s Hospital of Eastern Ontario (CHEO) Research Institute, CARE for RARE includes 21 academic sites across the country, and is recognized internationally as a pioneer in the field of genomics and personalized medicine.

Its team uses state of the art DNA sequencing technology to identify new rare disease genes for patients across Canada and around the world, and develops novel therapeutic approaches. Together, 80 physicians and 50 scientists work to advance rare disease research as part of the CARE for RARE program.

Currently, 25% rare disease patients wait 5-30 years for a diagnosis; 40% initially receive a misdiagnosis, and half will never receive a diagnosis. In contrast, the evidence-based approach being developed by CARE for RARE will result in an accurate rapid diagnosis for many affected by rare disease. Securing a clear diagnosis means that patients and families can make future projections about their healthcare, tap into best practice guidelines, seek reproductive counselling, and potentially start therapies.

In addition, only 5% of children with rare disease have access to an effective treatment. By investigating approved drugs for effectiveness in other diseases, CARE for RARE hopes to identify novel therapies for some of those currently without any treatment.

More information is also available at the Care4rare web page.

Related News

Research Projects

  1. Vamorolone versus placebo and prednisone in Duchenne muscular dystrophy: A randomized clinical trial

    01/10/2022

    Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder affecting 1 in 3600 to 9300 male newborns.1 Treatment with oral corticosteroids (prednisone, deflazacort) delays loss of ambulation,2 but long-term corticosteroid treatment causes weight gain, stunting of growth, osteoporosis, mood disturbances, adrenal insufficiency, and other safety concerns leading to poor adherence to practice guidelines.3,4

  2. Sickle Cell Bone Disease and Response to Intravenous Bisphosphonates in Children

    16/05/2022

    Our findings demonstrate that a wide range of SCD bone morbidity can present in childhood, and we report successful pain management with IV bisphosphonate therapy.

  3. Impact of Burosumab Compared with Conventional Therapy in Younger Versus Older Children with X-Linked Hypophosphatemia

    09/05/2022

    In this post hoc subgroup analysis using data from the phase 3 study of burosumab vs Pi/D in children with XLH aged 1 to 12 years (9), we explored the effect of burosumab vs Pi/D on phosphate homeostasis, growth, lower limb deformity, and safety outcomes for those younger (aged 1-< 5 years) vs older (aged 5-12 years) at study onset.

  4. Preventing symptomatic vitamin D deficiency and rickets among Indigenous infants and children in Canada

    01/05/2022

  5. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: A 30-month non-randomized open-label extension study

    25/01/2022

    We found that vamorolone, a novel dissociative steroidal anti-inflammatory drug, was not associated with a change in TTSTAND velocity from baseline to 30 months among boys with DMD aged 4 to 7 at enrollment.

  6. Dominant osteogenesis imperfecta with low bone turnover caused by a heterozygous SP7 variant

    07/01/2022

  7. Outcome of over 1500 matches through the Matchmaker Exchange for rare disease gene discovery: The 2-year experience of Care4Rare Canada

    01/01/2022

    Matchmaking through the MME is an effective way to investigate novel candidate genes; however, it is a labor-intensive process. Engagement from the community to contribute phenotypic, genotypic, and inheritance data will ensure that matchmaking continues to be a useful approach in the future.

  8. Musculoskeletal features in adults with X-linked hypophosphatemia: An analysis of clinical trial and survey data

    12/10/2021

    The findings from this study highlight the frequency of clinically important musculoskeletal features in adults with XLH and their early onset, illustrating a scenario of premature musculoskeletal morbidity compared with the general population.

  9. Insights into the expanding phenotypic spectrum of inherited disorders of biogenic amines

    20/09/2021

    Between January 1st 2015 and May 15th 2020, 429 patients were enrolled in the iNTD patient registry. Of these entries, 350 patients had a diagnosis of biogenic amine disorders. 75 patients who were transferred from the JAKE database on aromatic L-amino acid decarboxylase deficiency (http://www.biopku.org/home/jake.asp) were not analyzed in this study due to the high number of missing variables of interest. The remaining cohort of patients with disorders of biogenic amines consisted of 275 patients from 248 families (157 female (57%), from 42 countries: 196 patients born in Europe, 42 in North America, 34 in Asia, three in Central/South America and one in Africa). 109 patients had primary disorders of biogenic amine metabolism, 161 BH4 deficiencies (BH4Ds) and five patients DNAJC12D (Tables 2 and 3). All diagnoses were confirmed either by mutational analysis alone or by a combination of specific biochemical tests in CSF, urine and blood (Table 4).

  10. Incidence and short-term outcomes of Kawasaki disease.

    30/03/2021

    KD incidence is increasing in Ontario, with greater healthcare utilization from hospitalizations and subsequent follow-up.

  11. Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia

    23/01/2021

    In conclusion, changing to burosumab improved PRO measures, with statistically significant differences in PROMIS pain interference at week 40 versus continuing with conventional therapy and in PHS-10 at weeks 40 and 64 versus baseline.

  12. Genetic and metabolic investigations for individuals with neurodevelopmental disorders: a survey of Canadian geneticists’ practices

    01/01/2021

    Evidence-based guidelines should be developed to facilitate best practices in Canada.

  13. Assessment of longitudinal bone growth in osteogenesis imperfecta using metacarpophalangeal pattern profiles

    27/07/2020

    COL1A1 and COL1A2 mutations affect bone growth not only by inducing fractures and bone deformities, but also through longitudinal growth deficits in bones that do not fracture or deform.

  14. Utility and practice of electrodiagnostic testing in the pediatric population: An AANEM consensus statement

    02/11/2019

    The panel found that electrodiagnostic studies continue to have high utility for the diagnosis of numerous childhood neuromuscular disorders, and that standardized approaches along with the use of high‐quality reference values are important to maximize the diagnostic yield of these tests in infants, children, and adolescents.

  15. ALU transposition induces familial hypertrophic cardiomyopathy

    01/09/2019

    Our results demonstrate that haploinsufficiency resulting from MYBPC3 complete deletion, potentially mediated by Alu recombination, is an important disease mechanism in cardiomyopathy and emphasizes the importance of copy number variation analysis in patients clinically suspected of HCM.

  16. Epilepsy genetics: Current knowledge, applications, and future directions

    01/07/2018

    Drug screening with in vitro and in vivo models of epilepsy can potentially facilitate new treatment strategies.

  17. Benefits of early referral to pediatric palliative care for a child with a rare disease

    01/06/2018

    This case is described to provide a voice for families who are caring for a child with an undiagnosed or life-limiting illness and especially for the families who won’t consider PPC either out of fear or not knowing it exists.

  18. Iron Overload In Transfusion-Dependent Survivors Of Hemoglobin Bart’s Hydrops Fetalis

    03/05/2018

    While homozygous α0-thalassemia is currently considered a rare disease, its prevalence is likely to rise given the high α0-thalassemia gene carrier rates in Southeast Asia coupled with recent advances in fetal medicine that is delivering improved access to intra-uterine transfusions.

  19. Addressing Challenges in the Diagnosis and Treatment of Rare Genetic Diseases

    01/03/2018

    Here, we discuss the increasing opportunity for diagnosis and therapy of rare diseases and how to tackle the associated challenges.

  20. International Cooperation to Enable the Diagnosis of All Rare Genetic Diseases

    05/05/2017

    Provision of a molecularly confirmed diagnosis in a timely manner for children and adults with rare genetic diseases shortens their "diagnostic odyssey," improves disease management, and fosters genetic counseling with respect to recurrence risks while assuring reproductive choices.

  21. Utility of whole‐exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care

    01/03/2016

    In the next decade we will witness a paradigm shift in the way we care for patients with rare genetic diseases, addressing a significant gap in the management of individuals with rare diseases. The diagnostic journey for patients will include clinical genomic sequencing, which in the not too distant future will be WGS as costs decrease with new platforms. The accessibility of WGS‐based diagnostics for patients will be central to understanding the complete compendium of human genetic pathology. Strategies and infrastructure should be put in place to facilitate discovery in clinical settings, and to further mine large phenotypic and genomic datasets for disease mechanisms. As we understand the etiology of more rare diseases, it is probable that we will increasingly implicate known genes and that the approach to the completion of the complete Mendelian dataset will be asymptotic. There will be a subset of rare diseases that are due to non‐coding mutations in regulatory regions that may be more readily identified with the imminent use of WGS and RNA sequencing, and to implicate and understand this type of variation will require large‐scale data sharing at an impressive level. Ultimately, such datasets will be instrumental in identifying modifiers of disease, providing insight into phenotypic variability, prognosis, and for a subset of diseases, identifying drug targets. Finally, NGS technologies are providing significant opportunities to implement personalized health strategies including prevention or early detection of disease, improved health maintenance, and development of tailored therapy for patients with rare genetic diseases.

  22. Biallelic Mutations in BRCA1 Cause a New Fanconi Anemia Subtype

    01/08/2015

    The proband presented at birth with microsomia and dysmorphic features (Fig. 1A). Growth parameters were less than the 0.4 percentile at term (birth weight 1990g, height 40.5 cm, head circumference (HC) 27 cm), and subsequent catch-up growth was not evident at 25 years of age (weight 40 kg, −3.03 S.D.; 135 cm tall, −4.35 S.D.; HC 48.5 cm, approx.−4 to −5 S.D.). Additional congenital abnormalities included sparse hair, upslanted palpebral fissures, blepharophimosis, a narrow palate, dental malocclusion, a high-pitched and hoarse voice, hyper and hypopigmented skin lesions, duodenal stenosis and a slightly enlarged left kidney. She has proximally inserted thumbs (Fig. 1A), 2nd digit camptodactyly, 2–3 toe syndactyly and hyperextensible knees as well as a history of hip dislocation. Conductive hearing loss was diagnosed at 4 years of age. Bone age at 2y 3m was delayed (1y and 6m (−2S.D.)), but had normalized by 9 years. The patient also has mild intellectual disability with significantly delayed speech. At 23 years of age she was diagnosed with ductal breast carcinoma that was estrogen and progesterone receptor positive and Her2 negative. Mastectomy was performed followed by treatment with docetaxel, fluorouracil-epirubicin-cyclophosphamide and radiation therapy. A prophylactic mastectomy was performed on the contralateral breast at age 25. The patient did not experience unusual treatment associated toxicity and has not been diagnosed with bone marrow failure to date.

  23. Evidence for Clinical, Genetic and Biochemical Variability in Spinal Muscular Atrophy With Progressive Myoclonic Epilepsy

    01/12/2014

    The results of the WES and the functional studies prompted an electromyography (EMG) study that showed evidence of motor neuron disease despite only mild proximal muscle weakness.

  24. Mutations in PIK3R1 Cause SHORT Syndrome

    06/06/2013

    Our findings show that PIK3R1 mutations are the major cause of SHORT syndrome and suggest that the molecular mechanism of disease might involve downregulation of the PI3K-AKT-mTOR pathway.

  25. Targeted therapies for congenital myasthenic syndromes: systematic review and steps towards a treatabolome

    We assess the strength and quality of the evidence and create a dataset that provides the foundation for a computer-aided system to enable clinicians to gain easier access to information about treatable variants and the evidence they need to consider.

Researchers

  1. Kym M Boycott

    Senior Scientist, CHEO Research Institute

    View Profile Email
  2. David A. Dyment

    Investigator, CHEO Research Institute

    View Profile Email
  3. Helly Goez

    Investigator, CHEO Research Institute

    View Profile Email
  4. Olga Jarinova

    Investigator, CHEO Research Institute

    View Profile Email
  5. Eric LaCasse

    Associate Scientist, CHEO Research Institute

    View Profile Email
  6. Hanns Lochmüller

    Senior Scientist, CHEO Research Institute

    View Profile Email
  7. Private: Jean McGowan-Jordan

    Investigator, CHEO Research Institute

    View Profile Email
  8. Hugh McMillan

    Investigator, CHEO Research Institute

    View Profile Email
  9. Marie-Eve Robinson

    Investigator, CHEO Research Institute

    View Profile Email
  10. Sarah Sawyer

    Investigator, CHEO Research Institute

    View Profile Email
  11. Christina Vadeboncoeur

    Investigator, CHEO Research Institute

    View Profile Email
  12. Leanne Ward

    Senior Scientist, CHEO Research Institute

    View Profile Email
  13. Richard Webster

    Investigator, CHEO Research Institute

    View Profile Email

Family Leaders

  1. Adam Fobert

    View Profile
  2. Adeseun Ilori

    View Profile
  3. Andrew McVey

    View Profile
  4. Andy Statia

    View Profile
  5. Barb Shantz

    View Profile
  6. Bina Sharma

    View Profile
  7. Bleadon Anderson

    View Profile
  8. Carolyn Stiff

    View Profile
  9. Cassandra Schopf

    View Profile
  10. Christine Dalgleish

    View Profile
  11. Claire Dawe-McCord

    View Profile
  12. Dawn Pickering

    View Profile
  13. Ellen Song

    View Profile
  14. Erin Fobert

    View Profile
  15. Haishan Chen

    View Profile
  16. Jessica Hay

    View Profile
  17. Kate Stevens

    View Profile
  18. Kieran Peacock

    View Profile
  19. Laurie Woodward

    View Profile
  20. Leanne van der Zweep

    View Profile
  21. Lisa Wadden

    View Profile
  22. Madeleine Latour

    View Profile
  23. Madleen Zapata-Martinez

    View Profile
  24. Mairead Green

    View Profile
  25. Mariann Michael

    View Profile
  26. Natalie del Signore

    View Profile
  27. Natasha Baechler

    View Profile
  28. Samantha Bellefeuille

    View Profile
  29. Sheena Murphy

    View Profile
  30. Shelley Frappier

    View Profile
  31. Sofia Constantakis

    View Profile
  32. Trinity Lowthian

    View Profile